The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting. by Roberts, Emmert et al.
The diagnostic accuracy of the natriuretic peptides in
heart failure: systematic review and diagnostic
meta-analysis in the acute care setting
OPEN ACCESS
Emmert Roberts academic clinical fellow in psychiatry 1, Andrew J Ludman consultant cardiologist 2,
Katharina Dworzynski senior research fellow 3, Abdallah Al-Mohammad consultant cardiologist 4,
Martin R Cowie professor of cardiology 5, John J V McMurray professor of cardiology 6, Jonathan
Mant professor of primary care research 7, on behalf of the NICE Guideline Development Group for
Acute Heart Failure
1Maudsley Hospital, South London and the Maudsley Mental Health Trust, London, UK; 2Royal Devon & Exeter NHS Foundation Trust, Wonford,
Exeter EX2 5DW, UK; 3National Clinical Guideline Centre, Royal College of Physicians, London, UK; 4South Yorkshire Cardiothoracic Centre,
Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK; 5National Heart and Lung Institute, Imperial College London (Royal Brompton
Hospital), London, UK; 6British Heart Foundation (BHF) Cardiovascular Research Centre, University of Glasgow, Glasgow, UK; 7Primary Care Unit,
Department of Public Health & Primary Care, Strangeways Research Laboratory, University of Cambridge, Cambridge, UK
Abstract
Objectives To determine and compare the diagnostic accuracy of serum
natriuretic peptide levels (B type natriuretic peptide, N terminal probrain
natriuretic peptide (NTproBNP), and mid-regional proatrial natriuretic
peptide (MRproANP)) in people presenting with acute heart failure to
acute care settings using thresholds recommended in the 2012 European
Society of Cardiology guidelines for heart failure.
Design Systematic review and diagnostic meta-analysis.
Data sourcesMedline, Embase, Cochrane central register of controlled
trials, Cochrane database of systematic reviews, database of abstracts
of reviews of effects, NHS economic evaluation database, and Health
Technology Assessment up to 28 January 2014, using combinations of
subject headings and terms relating to heart failure and natriuretic
peptides.
Eligibility criteria for selecting studies Eligible studies evaluated one
or more natriuretic peptides (B type natriuretic peptide, NTproBNP, or
MRproANP) in the diagnosis of acute heart failure against an acceptable
reference standard in consecutive or randomly selected adults in an
acute care setting. Studies were excluded if they did not present sufficient
data to extract or calculate true positives, false positives, false negatives,
and true negatives, or report age independent natriuretic peptide
thresholds. Studies not available in English were also excluded.
Results 37 unique study cohorts described in 42 study reports were
included, with a total of 48 test evaluations reporting 15 263 test results.
At the lower recommended thresholds of 100 ng/L for B type natriuretic
peptide and 300 ng/L for NTproBNP, the natriuretic peptides have
sensitivities of 0.95 (95% confidence interval 0.93 to 0.96) and 0.99 (0.97
to 1.00) and negative predictive values of 0.94 (0.90 to 0.96) and 0.98
(0.89 to 1.0), respectively, for a diagnosis of acute heart failure. At the
lower recommended threshold of 120 pmol/L, MRproANP has a sensitivity
ranging from 0.95 (range 0.90-0.98) to 0.97 (0.95-0.98) and a negative
predictive value ranging from 0.90 (0.80-0.96) to 0.97 (0.96-0.98). At
higher thresholds the sensitivity declined progressively and specificity
remained variable across the range of values. There was no statistically
significant difference in diagnostic accuracy between plasma B type
natriuretic peptide and NTproBNP.
Conclusions At the rule-out thresholds recommended in the 2012
European Society of Cardiology guidelines for heart failure, plasma B
type natriuretic peptide, NTproBNP, and MRproANP have excellent
ability to exclude acute heart failure. Specificity is variable, and so
imaging to confirm a diagnosis of heart failure is required. There is no
statistical difference between the diagnostic accuracy of plasma B type
natriuretic peptide and NTproBNP. Introduction of natriuretic peptide
measurement in the investigation of patients with suspected acute heart
failure has the potential to allow rapid and accurate exclusion of the
diagnosis.
Correspondence to: A J Ludman a.ludman@nhs.net
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Introduction
Making the correct diagnosis in patients with suspected acute
heart failure is challenging, and confirmatory in only 40-50%
of cases. Several studies have shown that when added to routine
history, clinical examination, and conventional investigations
(for example, chest radiography), measurement of plasma
natriuretic peptide levels improves diagnostic accuracy, and has
led to these markers being recommended in international
guidelines for the diagnosis and management of heart failure.1 2
The 2012 European Society of Cardiology guidelines for heart
failure endorsed specific age independent decision cut-offs for
plasma B type natriuretic peptide (≤100 ng/L), N terminal
probrain natriuretic peptide (NTproBNP, ≤300 ng/L), and
mid-regional proatrial natriuretic peptide (MRproANP, ≤120
pmol/L) for the exclusion of acute heart failure based on
consensus of expert opinion.2 3 Although natriuretic peptide
levels have been used widely for the earlier diagnosis or
exclusion of chronic heart failure in the outpatient setting, their
use in the acute care setting has only partially been adopted,
because their role has remained uncertain and they are not
routinely available in emergency departments in the United
Kingdom for rapid assessment of patients presenting with
breathlessness. This lack of availability reflects lack of clarity
on the diagnostic accuracy of natriuretic peptides in this setting.
In particular, while the age independent cut-offs as
recommended by the European Society of Cardiology are
relatively easy to apply in clinical practice, they have not been
evaluated by diagnostic meta-analysis. As part of the
development process of a National Institute for Health and Care
Excellence guideline on the management of acute heart failure
we performed an up to date, diagnostic meta-analysis of the
utility of plasma B type natriuretic peptide, NTproBNP, and
MRproANP in acute and hospital based care settings at the
thresholds recommended by the European Society of Cardiology
guidelines.
Methods
Types of studies
We considered studies to be eligible if they evaluated one or
more natriuretic peptides (B type natriuretic peptide, NTproBNP,
or MRproANP) in the diagnosis of heart failure against an
acceptable reference standard in a consecutive or randomly
selected series of adults (age ≥18 years) in an acute care setting.
The reference standard was the diagnosis of heart failure by
retrospective review or the final hospital diagnosis. Studies were
excluded if they did not present sufficient data to allow us to
extract or calculate absolute numbers of true positives, false
positives, false negatives, and true negatives or to report age
independent natriuretic peptide thresholds. Studies were also
excluded if they were not available in English.
For each natriuretic peptide, we grouped data according to
prespecified age independent thresholds from the 2012 European
Society of Cardiology guidelines for heart failure. Some studies
contributed data to more than one threshold analysis per peptide.
The ranges used were ≤100 ng/L, 100-500 ng/L, and >500 ng/L
for B type natriuretic peptide; ≤300 ng/L, 300-1800 ng/L, and
>1800 ng/L for NTproBNP; and ≤120 pmol/L and >120 pmol/L
for MRproANP.
We excluded studies examining the use of natriuretic peptides
in the diagnosis of heart failure in non-acute care settings, the
use of urinary natriuretic peptides, screening for left or right
ventricular dysfunction, and studies concerning the diagnostic
accuracy of natriuretic peptides in pleural effusion of unknown
cause.
Search strategies
For the search strategies we used a combination of subject
headings and terms relating to the target condition of interest
(heart failure) and the index tests (natriuretic peptides: B type
natriuretic peptide, NTproBNP, and MRproANP). Using the
search terms and strategies described in the supplementary file
we searched Medline, Embase, Cochrane central register of
controlled trials, Cochrane database of systematic reviews,
database of abstracts of reviews of effects, NHS economic
evaluation database, and Health Technology Assessment up to
28 January 2014.
Selection of studies
One author (ER) initially assessed the titles and then abstracts
of papers identified by the search. Two authors (ER and KD)
reviewed the full text of the remaining articles. Any discrepancy
was resolved by discussion. Where agreement could not be
reached, we consulted a third author (JM or AL). Excluded
studies are listed in the online supplementary material.
Data extraction and management
Two authors (ER and KD) independently extracted a standard
set of data, with discrepancies resolved by discussion. Where
more than one type of assay for the same index test was used
(for example, Abbott or Biosite BNP), the more conservative
estimate of sensitivity was extracted and included in the review.
For each comparison of index test at a particular threshold with
a reference standard, we extracted data on the number of true
positives, true negatives, false positives, and false negatives.
Assessment of methodological quality
Two authors (ER and KD) independently assessed the quality
of each study using the QUADAS-II checklist (www.bris.ac.
uk/quadas/quadas-2).
Statistical analysis and data synthesis
The comparisons made in this review can be considered in two
parts. The first comparison was among studies using the same
individual peptide (B type natriuretic peptide, NTpro-BNP,
MRpro ANP) according to the three threshold categories. The
second comparison was between different peptides at
“equivalent” thresholds for ruling out heart failure, as specified
in the 2012 European Society of Cardiology guidelines for heart
failure. Comparative analyses were conducted across all included
studies as well as within studies, with direct comparisons
between tests with the same participants. Analyses were
conducted in Review Manager version 5.3 and STATA SE
version 12.
For each natriuretic peptide at the prespecified threshold, we
plotted estimates of the paired observed sensitivities and
specificities in forest plots and as average summary receiver
operating characteristic (sROC) curves. These plots show the
variation in accuracy between studies. Where adequate data
were available we carried out diagnostic meta-analyses. To be
able to pool data we required five or more studies for each
threshold. We used the bivariate method modelled in Winbugs
(Medical Research Council Biostatistics Unit) to pool test
accuracy for the studies. The bivariate method uses logistic
regression on the true positives, true negatives, false positives,
and false negatives reported in the studies. We constructed
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sROCs and plotted confidence regions (using methods outlined
by Novielli and colleagues4). The average operating point for
each test was identified on each curve, and average sensitivities
and specificities computed. Where insufficient data were
available to estimate all variables, we simplified the sROC
model by assuming a symmetrical shape to the sROC curve.
We assessed the significance of the difference in test
performance by using a likelihood ratio test comparing models
with and without covariate terms for accuracy at equivalent
thresholds.
Investigation of publication bias and
heterogeneity
To assess for the possibility of publication bias for each peptide
at each threshold, we constructed funnel plots and performed
Deeks’ funnel plot asymmetry test, with a P value greater than
0.1 indicating no publication bias. We predefined heterogeneity
as an I2 statistic greater than 50%, and calculated I2 for each
analysis where there were sufficient studies (>5) for diagnostic
meta-analysis.Where heterogeneity was shown, we investigated
variation in sensitivity and specificity by adding to the
meta-analysis models prespecified covariates indicating acute
care setting of presentation, assay of natriuretic peptide used in
the study cohort, prevalence of acute heart failure, and overall
study quality. We did not carry out sensitivity analyses.
Results
The search identified 7007 papers, of which 6856 were excluded
on the basis of the title and abstract. Full text articles were
retrieved for 151 titles, of which 109 were excluded:
non-diagnostic accuracy studies (n=47); non-acute care setting
(n=33); systematic reviews (n=14), cross checked for includable
references; not available in English (n=8); and unable to extract
absolute numbers of true positives, false positives, false
negatives, and true negatives (n=7). (See the supplementary file
for the PRISMA flow diagram and table showing excluded
studies.)
A total of 37 unique study cohorts described in 42 study reports
were included in the review. In eight of the 37 study cohorts
more than one test was evaluated. Thus a total of 48 test
evaluations reported a total of 15 263 test results. The reference
standard diagnosis of heart failure was a clinical diagnosis of a
syndrome inwhich patients have typical symptoms (for example,
dyspnoea and peripheral oedema) and signs (for example, raised
jugular venous pressure and pulmonary crepitations) resulting
from an abnormality of cardiac structure or function.
Retrospective clinical review was the reference standard for 36
test evaluations, and discharge or final hospital diagnosis for
12. Table 1⇓ shows the reference standards described in
individual studies.
The accuracy of B type natriuretic peptide was assessed in 26
study cohorts. In 19 cohorts (6950 participants) data were
reported at the ≤100 ng/L threshold, in 20 cohorts (4543
participants) at the 100-500 ng/L threshold, and in four cohorts
(283 participants) at the ≥500 ng/L threshold.
The accuracy of NTproBNP was assessed in 18 study cohorts.
In 10 cohorts (3349 participants) data were reported at the ≤300
ng/L threshold, in 13 cohorts (3223 participants) at the 300-1800
ng/L threshold, and in three cohorts (840 participants) at the
≥1800 ng/L threshold.
The accuracy ofMRproANPwas assessed in four study cohorts.
In two cohorts (1892 participants) data were reported at the
≤120 pmol/L threshold and in three cohorts (916 participants)
at the >120 pmol/L threshold. Table 1 provides a summary of
the studies assessing each natriuretic peptide.
Methodological quality of included studies
We used four quality categories (patient selection, reference
standard, index test, and flow and timing) to evaluate the risk
of bias and applicability of each study cohort and designated
an overall high or low risk of bias for each category (see table
1). Just over 50% of the studies included a representative
spectrum of participants attending acute care settings with
symptoms suggestive of acute heart failure; most of the
remaining studies had inappropriate patient exclusion criteria
based on our prespecified patient cohort or had not adequately
described the sampling methods. Around 65% of the studies
reported blinding of the reference standard to the results of the
index test, and around 70% reported blinding of the index test
to the results of the reference standard. Only around 60% either
explained any withdrawals or was clear that there were no
withdrawals and had appropriate sequencing of tests.
B type natriuretic peptide
When diagnostic meta-analysis was conducted the pooled
sensitivity, specificity, positive predictive value, and negative
predictive value of B type natriuretic peptide at a threshold of
≤100 ng/L were 0.95 (95% confidence interval 0.93 to 0.96),
0.63 (0.52 to 0.73), 0.67 (0.63 to 0.75), and 0.94 (0.90 to 0.96),
respectively. At a B type natriuretic peptide level of 100-500
ng/L, the pooled sensitivity, specificity, positive predictive
value, and negative predictive value were 0.85 (0.81 to 0.88),
0.86 (0.79 to 0.91), 0.85 (0.78 to 0.90), and 0.86 (0.82 to 0.89),
respectively. As only four study cohorts reported data for B type
natriuretic peptide at a threshold of ≥500 ng/L, diagnostic
meta-analysis was not performed and the reported sensitivity
from the study cohorts ranged from 0.35 (range 0.17-0.56) to
0.83 (0.69-0.92) and the paired specificity from 0.78 (0.56-0.93)
to 1.0 (0.91-1.0). At the lowest threshold (<100 ng/L) sensitivity
was consistently high whereas specificity varied widely across
all studies (0.26-0.94). As the threshold increased, sensitivity
decreased (that is, more cases of heart failure would be missed)
and specificity increased yet remained quite variable (fig 1⇓).
Figure 2⇓ provides additional information, displaying the
summary sensitivity and specificity points compared with the
forest plots in figure 1. The summary point for the threshold of
100-500 ng/L is clearly lower in the sROC space compared with
the <100 ng/L threshold, suggesting diagnoses of heart failure
would be missed, although the specificity was higher.
N terminal probrain natriuretic peptide
When diagnostic meta-analysis was conducted, the pooled
sensitivity, specificity, positive predictive value, and negative
predictive value of NTproBNP at a threshold of ≤300 ng/L were
0.99 (95% confidence interval 0.97 to 1.00), 0.43 (0.26 to 0.62),
0.64 (0.57 to 0.73), and 0.98 (0.89 to 1.0), respectively; and at
300 to 1800 ng/L these variables were 0.90 (0.86 to 0.93), 0.76
(0.69 to 0.82), 0.80 (0.74 to 0.84), and 0.88 (0.82 to 0.92),
respectively. As only three study cohorts reported data for
NTproBNP at a threshold of ≥1800 ng/L, diagnostic
meta-analysis was not performed and the reported sensitivity
ranged from 0.67 (range 0.60-0.73) to 0.87 (0.81-0.92) and the
paired specificity from 0.72 (0.63-0.80) to 0.95 (0.91-0.98). The
pattern in figures 3⇓ and 4⇓ mirrors that of B type natriuretic
peptide at different thresholds—that is, decreasing sensitivity
and increasing specificity with increasing threshold. The
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summary points in figure 4 clearly indicate a decrease in mean
sensitivity by threshold.
Mid-regional proatrial natriuretic peptide
As only four study cohorts reported data for MRproANP,
diagnostic meta-analysis was not performed. At a threshold of
≤120 pmol/L the sensitivity of MRproANP ranged from 0.95
(range 0.90-0.98) to 0.97 (0.95-0.98) and the paired specificity
ranged from 0.56 (0.47-0.65) to 0.60 (0.57-0.63). At a threshold
of >120 pmol/L the sensitivity ranged from 0.84 (0.77-0.89) to
0.98 (0.94-1.00) and the paired specificity from 0.40 (0.34-0.46)
to 0.84 (0.77-0.90). With data from only four study cohorts
available, the pattern for MRproANP was less clear, with
sensitivity remaining high across the two thresholds, although
the specificity was variable (figs 5⇓ and 6⇓).
Comparisons between natriuretic peptides
After diagnostic meta-analysis was conducted, there was a clear
overlap of the confidence regions for B type natriuretic peptide
versus NTproBNP surrounding the pooled sensitivity and
specificity. This overlap suggested no statistically significant
difference between tests at the rule-out thresholds of ≤100 ng/L
and ≤300 ng/L, respectively (P>0.05) (fig 7⇓).
Using the upper and lower confidence limits of the sensitivity
at the rule-out thresholds, the number of false negatives per
1000 were calculated assuming a prevalence ranging from 0.23
to 0.82 (the range in the included study cohorts). At a prevalence
of 0.23 there were between 0 and 7 or 9 and 16 false negative
diagnoses per 1000; and at a prevalence of 0.82 there were
between 33 and 57 or 0 and 25 false negative diagnoses per
1000, if employing a B type natriuretic peptide strategy or an
N terminal probrain natriuretic peptide strategy, respectively.
Investigations of publication bias and
heterogeneity
Deeks’ funnel plot asymmetry test revealed no evidence of
publication bias for any peptide at any threshold (see
supplementary file). Table 2⇓ presents the I2 statistics for each
peptide at each threshold. I2 statistics were, as expected in
diagnostic meta-analyses, universally more than 50%, owing
to differences in patients’ underlying diagnoses and
comorbidities. Heterogeneity investigations were undertaken
to test for differences in natriuretic peptide performance only
where sufficient (≥5) study cohorts existed to perform diagnostic
meta-analysis. The only significant difference was for
NTproBNP≤300ng/L; when adding prevalence differences into
the model the specificity was significantly higher at 0.93 (95%
confidence interval 0.84 to 0.97, P<0.01). No other significant
difference in sensitivity or specificity was noted for all other
covariates for all peptides at each studied threshold. Table 3⇓
shows the results.
Discussion
This meta-analysis of the diagnostic accuracy of natriuretic
peptide use was performed to inform recommendations within
the new National Institute for Health and Care Excellence
guideline for the diagnosis and management of people with
suspected heart failure in the acute care setting. It is the largest
meta-analysis of the use of natriuretic peptides specifically in
the acute care setting, and the first to specifically investigate
and compare the different natriuretic peptides at the cut-off
thresholds defined within the 2012 European Society of
Cardiology guidelines for heart failure for the diagnosis and
exclusion of acute heart failure.2 Our results show that both B
type natriuretic peptide and N terminal probrain natriuretic
peptide (NTproBNP) have excellent ability to exclude the
diagnosis of acute heart failure at their respective lower cut-off
thresholds, with sensitivities approaching 1 and will therefore
miss few, if any, cases of possible acute heart failure when used
as a rule-out test. Mid-regional proatrial natriuretic peptide
(MRproANP) at a threshold of <120 pmol/L also has a
sensitivity close to 1, but there are too few suitable studies to
date with which to perform ameta-analysis, and the investigation
is not yet widely available as a clinical test. The sensitivity of
B type natriuretic peptide, NTproBNP, and MRproANP for the
diagnosis of acute heart failure at thresholds above this lower
cut-off is only modest. Specificity is also relatively low
(although it increases with increasing natriuretic peptide value),
thus confirmatory testing by cardiac imaging is required.
The diagnosis of heart failure is often challenging: the symptoms
and signs may be non-specific and may occur in other
non-cardiac diseases. The mortality from acute heart failure
remains high, at approximately 25% over one year,47 and this
may be reduced by prompt diagnosis and treatment. The early
use of a natriuretic peptide test to rule out acute heart failure,
at the diagnostic thresholds evaluated in this meta-analysis, can
reliably exclude heart failure and allowmore rapid investigation
of other potential causes for a patient’s symptoms. A negative
test result may reduce or obviate the need to proceed to
echocardiography or other cardiac imaging, allowing more
efficient use of resources. In a similar fashion, in patients where
the clinical assessment is difficult, the ability to rapidly raise
the suspicion of acute heart failure when the result for natriuretic
peptide is above the cut-off, will allow targeted, rapid
investigation to confirm or refute the diagnosis. Earlier
confirmation of the diagnosis of heart failure may facilitate more
rapid initiation of specific treatment, potentially shortening
hospital stay and reducing mortality.48
WhenB type natriuretic peptide was comparedwith NTproBNP,
there was no statistically significant difference in their diagnostic
ability at the rule-out thresholds examined. When converted to
absolute patient numbers the use of B type natriuretic peptide
rather than NTproBNP in an acute care setting potentially
increased the false negative test results by between 8 and 31
more people per 1000 people (assuming a prevalence ranging
from 0.23 to 0.82, the range in the included study cohorts).
Sensitivity was similar and specificity only modest for both
natriuretic peptides in the low to intermediate ranges of
measured values. Therefore it is important that for values
measured above the rule-out thresholds, the information is
correlated with clinical and imaging assessment to confirm a
diagnosis of heart failure and to exclude non-cardiac causes of
an increased natriuretic peptide level (such as pulmonary
embolus, sepsis, or renal failure).3 Similarly, once heart failure
is thought to be likely because of clinical and natriuretic peptide
evidence, further assessment (generally with echocardiography)
is required to confirm the diagnosis and inform future
management.
As with any test, the pretest probability is important and the
result must be interpreted in the clinical context. If the clinical
scenario is strongly suggestive of heart failure or, conversely,
points towards an alternative diagnosis, there is no need to
perform the assay for diagnostic purposes. For example, in a
patient in whom dyspnoea is associated with a known cause,
such as an adult presenting with trauma, measurement of the
natriuretic peptide level is not needed.
In the United Kingdom the availability and use of natriuretic
peptides is patchy and tests are not routinely available in acute
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care settings, despite accumulating evidence and national
guidelines advocating their use.4 The barriers to introduction
and use have not been reported but we speculate them to include
perceived excessive additional cost, a perceived lack of
additional diagnostic value, or uncertainty as to which natriuretic
peptide to use and their relative merits.
A previous meta-analysis comparing B type natriuretic peptide
with NTproBNP in the setting of acute heart failure only
evaluated studies that compared paired sampling of both
natriuretic peptides.49 Therefore, although diagnostic accuracy
data were reported for each natriuretic peptide, not all relevant
studies were included. However, no significant difference was
found between B type natriuretic peptide andNTproBNP, which
agrees with our findings. Worster and colleagues50 performed
a meta-analysis of nine studies (six for B type natriuretic peptide
and three for NTproBNP), published during or before 2004,
evaluating the use of natriuretic peptides in acute care settings
for the diagnosis of dyspnoea. Worster and colleagues also
reported no difference between B type natriuretic peptide and
NTproBNP, with similarly high diagnostic sensitivity and
modest specificity. However, our analysis included a
significantly larger numbers of studies, was not limited to
dyspnoea, as people may present acutely with several different
symptoms, and evaluated the accuracy at specific cut-off points
to inform current clinical practice. A meta-analysis of
MRproANP in the evaluation of dyspnoea in the emergency
department51 showed a diagnostic pooled sensitivity of 0.90
(95% confidence interval 0.88 to 0.92) and pooled specificity
of 0.68 (0.66 to 0.70) for the diagnosis of heart failure. However,
our specific analysis of age independent data using the suggested
rule-out threshold of <120 pmol/L gives a higher sensitivity of
0.95 (0.90 to 0.98) and paired specificity of 0.56 (0.47 to 0.65),
suggesting that measurement of MRproANP may also be a
valuable rule-out test for heart failure. Whether or not the test
offers any other specific additional advantage remains to be
determined.
The exhaustive meta-analysis performed shows that both B type
natriuretic peptide and NTproBNP have similar, excellent
negative predictive value. Therefore, whichever natriuretic
peptide is available locally can be used reliably. No statistically
significant differences were detected for their use within a
specific care setting or by type of assay used (point of care or
laboratory test).
Limitations of this study
The diagnostic values and cut-off thresholds for use of
natriuretic peptides in people with suspected heart failure in the
outpatient setting are different—associated with different
(generally reduced) sensitivity and specificity—and so the
results presented here are only applicable to patients presenting
acutely. We have examined age independent cut-off values to
validate the recommendations of the European Society of
Cardiology guideline and to allow ease of introduction in acute
clinical settings. A negative test result remains reassuring at
any age, and the impact of factors affecting the serum level of
natriuretic peptide (sex, age, body mass index) is less
pronounced in acute heart failure than in chronic heart failure.
The level of serum natriuretic peptide may increase with age,
reducing the specificity in some groups, but this will not affect
sensitivity.
Most studies in this review were performed within the
emergency department, but we also included studies in other
acute settings if natriuretic peptide was being used to
differentiate heart failure from other diagnoses. As diagnostic
thresholds vary depending on clinical characteristics, this may
limit applicability in some settings. Studies in patients after
cardiac surgery were specifically excluded and in studies with
a higher previous risk or prevalence of acute heart failure the
negative predictive value and sensitivity would tend to be lower.
In most studies the ideal diagnostic test was taken as a
retrospective synthesis of clinical and imaging data, but was
heterogeneous between studies. This is not likely to have
affected the sensitivity results to any major degree but may
account partly for variability in reported specificity. An
individual patient meta-analysis would be technically possible
to address this research question, but it is unlikely to expand
further on the current review owing to the observed high
sensitivity and negative predictive values calculated in an overall
population of widely varying prevalence.
In this analysis we did not examine the role of natriuretic peptide
use in guiding treatment or in informing prognosis in this setting.
AlthoughB type natriuretic peptide andNTproBNP are routinely
available in hospital laboratories,MRproANP remains primarily
a research tool.
Conclusions
The use of NTproBNP and B type natriuretic peptide at the
rule-out threshold recommended by the recent European Society
of Cardiology guidelines on heart failure provides excellent
ability to exclude acute heart failure in the acute setting with
reassuringly high sensitivity. The specificity is modest at all but
the highest values of natriuretic peptide, therefore confirmatory
testing by cardiac imaging is required in patients with positive
test results. Use of natriuretic peptidemay allow the streamlining
of investigation, potentially leading to cost savings through
removing or reducing the need for echocardiography in patients
with natriuretic peptide levels below the cut-off threshold or by
facilitating more rapid investigation of non-cardiac disease.
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What is already known on this topic
Acute heart failure is the commonest cause of hospital admission in the United Kingdom in people aged over 65 years, and mortality
remains high
Diagnosis of acute heart failure is often difficult and the measurement of serum natriuretic peptides in the acute setting may be useful,
but has not been widely adopted in the United Kingdom
The 2012 European Society of Cardiology (ESC) guidelines for heart failure suggested rule-out thresholds for natriuretic peptides in the
acute setting, but the diagnostic accuracy at these thresholds is not known
What this study adds
At the rule-out thresholds recommended in the 2012 ESC guidelines for heart failure, B type natriuretic peptide, N terminal probrain
natriuretic peptide, and mid-regional proatrial natriuretic peptide have excellent ability to exclude acute heart failure and miss few cases
The specificity of the natriuretic peptides is modest and variable, and therefore confirmatory diagnostic testing by cardiac imaging is
required in the case of positive results
The addition of testing for serum natriuretic peptides to acute care settings in patients with suspected heart failure has the potential to
accurately streamline investigation and improve the early detection of heart failure
previous three years; no other relationships or activities that could appear
to have influenced the submitted work.
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that any discrepancies from the study as planned have been explained.
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Tables
Table 1| Characteristics of included studies
Quality (QUADAS-II)Reference standardIndex test (assay)
Prevalence
(%)
No of
men/womenDesign
No
(mean
age)Study, setting
Patient selection: high; index test:
high; reference standard: high;
flow and timing: low; overall: high
Clinical diagnosis based
on intent to treat heart
failure with diuretics for
24 hours
BNP inhouse assay43/123 (35)69/54Prospective
cohort
123 (68)Fleischer 1997,5 acute
admissions
Patient selection: high; index test:
low; reference standard: low; flow
and timing: low; overall: high
Retrospective review by
two cardiologists
BNP Triage (Biosite,
USA)
97/250 (39)235/15Cross
sectional
250 (63)Dao 2001,6 emergency
department
Patient selection: high; index test:
low; reference standard: low; flow
and timing: low; overall: high
Retrospective review by
two cardiologists and
one pulmonologist
BNP Triage (Biosite,
USA)
115/163
(71)
109/54Cross
sectional
163 (71)Logeart 2002,7 intensive
care unit
Patient selection: low; index test:
low; reference standard: low; flow
and timing: low; overall: low
Retrospective review by
two cardiologists
BNP Triage (Biosite,
USA)
744/1586
(47)
888/698Prospective
cohort
1586 (64)Maisel 2002,8
emergency department
Patient selection: low; index test:
low; reference standard: low; flow
and timing: low; overall: low
Retrospective review by
one cardiologist
BNP Triage (Biosite,
USA)
36/70 (51)33/37Cross
sectional
70 (72)Villacorta 2002,9
emergency department
Patient selection: high; index test:
low; reference standard: low; flow
and timing: low; overall: high
Retrospective review by
two cardiologists
BNP Triage (Biosite,
USA) (+3 inhouse
developed assays; not
extracted in this
analysis)
70/205 (34)100/105Prospective
cohort
205 (70)Lainchbury 2003,10
emergency department.
Only BNP results
extracted. NTproBNP
from pooled results in
Januzzi 200611
Patient selection: low; index test:
low; reference standard: low; flow
and timing: low; overall: low
Retrospective review by
committee of physicians
BNP inhouse assay32/52 (62)21/31Prospective
cohort
52 (74)Davis 2004,12
emergency department
Patient selection: high; index test:
low; reference standard: low; flow
and timing: low; overall: high
Retrospective review by
one cardiologist
BNP Triage (Biosite,
USA)
70/122 (57)62/60Cross
sectional
122 (56)Dokanish 2004,13
inpatients
Patient selection: low; index test:
high; reference standard: high;
flow and timing: low; overall: high
Retrospective review by
one cardiologist
BNP Triage (Biosite,
USA)
57/98 (58)100/0Prospective
cohort
98 (65)Barcase 2004,14
emergency department
Patient selection: low; index test:
low; reference standard: low; flow
and timing: low; overall: low
Retrospective review by
two experts
BNP Triage (Biosite,
USA)
141/308
(46)
154/154Cross
sectional
308 (80)Ray2004,15 emergency
department (overlap
with Ray 2005.23 Only
BNP results extracted
Patient selection: high; index test:
low; reference standard: low; flow
and timing: low; overall: high
Retrospective review by
two cardiologists
BNP Triage (Biosite,
USA), NTproBNP
Elecsys (Roche, USA)
60/160 (38)76/84Cross
sectional
160
(80.1)
Ailbay 2005,16
emergency department
Patient selection: high; index test:
low; reference standard: high;
flow and timing: low; overall: high
Retrospective review by
two cardiologists and
one pulmonologist
BNP Triage (Biosite,
USA)
32/70 (46)35/35Prospective
cohort
70 (NR)Arques 2005,17 acute
referrals
Patient selection: high; index test:
low; reference standard: low; flow
and timing: high; overall: high
Consensus of two senior
emergency department
physicians
BNP Triage (Biosite,
USA), NTproBNP
Elecsys (Roche, USA),
MRproANP LIA
(B.R.A.H.M.S,
Germany)
115/378
(30)
190/188Prospective
cohort
378 (78)Chenevier-Gobeaux
2005,18 emergency
department. Results
without renal function
stratification from
Chenevier-Gobeaux
201019
Patient selection: low; index test:
low; reference standard: low; flow
and timing: low; overall: low
Retrospective review by
one study investigator
BNP Abbott Architecht
(Abbott Diagnostics,
Netherlands),
NTproBNP Elecsys
(Roche, USA),
MRproANP LIA
137/251
(55)
234/17Prospective
cohort
251
(72.8)
Mueller 2005,20
emergency department.
MRproANP results from
Gegenhuber 200621
(B.R.A.H.M.S,
Germany)
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Table 1 (continued)
Quality (QUADAS-II)Reference standardIndex test (assay)
Prevalence
(%)
No of
men/womenDesign
No
(mean
age)Study, setting
Patient selection: high; index test:
low; reference standard: low; flow
and timing: low; overall: high
Retrospective chart
review
BNP Triage (Biosite,
USA)
47/70 (68)24/46Retrospective
cohort
70 (76.5)Parab 2005,22
emergency department
Patient selection: low; index test:
low; reference standard: low; flow
and timing: low; overall: low
Retrospective review by
two experts
NTproBNP Elecsys
(Roche, USA)
88/202 (44)100/102Cross
sectional
202 (80)Ray2005,23emergency
department. Overlap
with Ray 2004.15 Only
NTproBNP results
extracted
Patient selection: low; index test:
high; reference standard: high;
flow and timing: low; overall: high
Diagnosis recorded at
discharge on basis of
clinical and instrumental
investigations
NTproBNP Elecsys
(Roche, USA)
56/122 (46)58/64Prospective
cohort
122 (78)Zaninotto 2005,24
emergency department
Patient selection: low; index test:
low; reference standard: low; flow
and timing: low; overall: low
Retrospective review by
two cardiologists
NTproBNP Elecsys
(Roche, USA)
142/254
(56)
123/133Prospective
cohort
254 (81)Berdague 2006,25
emergency department
Patient selection: low; index test:
high; reference standard: high;
flow and timing: low; overall: high
Retrospective review by
one cardiologist
BNP Triage (Biosite,
USA)
72/143 (50)63/80Prospective
cohort
143 (79)Chung 2006,26
emergency department
Patient selection: high; index test:
low; reference standard: low; flow
and timing: low; overall: high
Retrospective review
utilising European
society of cardiology
guidelines. “Suitable for
pooling across studies”
NTproBNP Elecsys
(Roche, USA)
720/1256
(57)
641/615Pooled
prospective
trial data
1256
(68.3)
Januzzi 2006,11
emergency department;
comprising pooled data
from Lainchbury 2003,10
Bayes-Genis 2004,27
and Januzzi 2005,28 and
unpublished registry
data
Patient selection: high; index test:
low; reference standard: high;
flow and timing: low; overall: high
Diagnosed according to
symptoms and signs and
electrocardiography,
chest radiography, and
in some cases
echocardiography
BNP Access
(Beckman Coulter,
USA) (+ BNP Advia
(Bayer Diagnostics,
USA) not extracted),
NTproBNP Elecsys
(Roche, USA)
45/75 (60)NRProspective
cohort
75 (75)Sanz 2006,29 emergency
department
Patient selection: high; index test:
low; reference standard: low; flow
and timing: low
Retrospective review by
two cardiologist and one
respiratory physician
BNP Triage (Biosite,
USA)
22/41 (54)17/24Prospective
cohort
41 (NR)Arques 2007,30
emergency department
Patient selection: high; index test:
low; reference standard: low; flow
and timing: high; overall: high
Retrospective review by
cardiologist and
pulmonologist
BNP Triage (Biosite,
USA), NTproBNP
Elecsys (Roche, USA)
40/80 (50)44/36Retrospective
cohort
80 (74)Gorissen 2007,31
emergency department
Patient selection: high; index test:
low; reference standard: low; flow
and timing: low; overall: high
Retrospective review by
two intensivists
BNP Triage (Biosite,
USA)
23/74 (31)45/35Prospective
cohort
74 (NR)Karmpaliotis 2007,32
intensive care unit
Patient selection: high; index test:
low; reference standard: low; flow
and timing: low; overall: high
Retrospective review by
two cardiologists
NTproBNP Elecsys
(Roche, USA)
122/149
(82)
98/51Prospective
cohort
149 (NR)Gargani 2008,33
cardiology and
pulmonary admissions
Patient selection: low; index test:
low; reference standard: low; flow
and timing: low; overall: low
Based on clinical signs,
chest radiography,
echocardiography,
and/or radionuclide
angiography
BNP Access
(Beckman Coulter,
USA), NTproBNP
Elecsys (Roche, USA)
31/137 (23)77/60Prospective
cohort
137 (69)Gruson 2008,34
emergency department
Patient selection: low; index test:
low; reference standard: low; flow
and timing: low; overall: low
Retrospective review by
study physician
NTproBNP Dimension
Dade (Dade-Behring,
USA)
122/401
(30)
205/196Prospective
cohort
401
(67.4)
Behnes 2009,35
emergency department
Patient selection: low; index test:
low; reference standard: low; flow
and timing: low; overall: low
Final hospital diagnosis
confirmed by
cardiologists and/or
intensivists
NTproBNP Elecsys
(Roche, USA)
238/441
(54)
271/170Prospective
cohort
441
(59.1)
Klemen 2009,36
prehospital emergency
Patient selection: low; index test:
high; reference standard: high;
flow and timing: low; overall: high
Retrospective review by
two cardiologists and
one respiratory physician
NTproBNP Elecsys
(Roche, USA)
64/145 (44)NRProspective
Cohort
145 (NR)Nazarian 2009,37
emergency department
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Table 1 (continued)
Quality (QUADAS-II)Reference standardIndex test (assay)
Prevalence
(%)
No of
men/womenDesign
No
(mean
age)Study, setting
Patient selection: high; index test:
high; reference standard: high;
Retrospective review by
two cardiologists
BNP (5 sites Triage,
Biosite, USA, 2 site
Abbott, Netherlands)
368/740
(50)
399/341Prospective
cohort
740 (NR)Rogers 2009,38
emergency department
flow and timing: high; overall:
high
Patient selection: high; index test:
low; reference standard: low; flow
and timing: low; overall: high
Retrospective review by
one physician and one
cardiologist
BNP Abbott Architecht
(Abbott Diagnostics,
Netherlands)
274/612
(45)
328/284Retrospective
cohort
612
(74.5)
Lokuge 2010,39
emergency department
Patient selection: low; index test:
low; reference standard: low; flow
and timing: low; overall: low
Retrospective review by
two cardiologists
BNP Triage (Biosite,
USA), MRproANP LIA
(B.R.A.H.M.S,
Germany)
568/1641
(39)
859/782Prospective
cohort
1641
(NR)
Maisel 2010,40
emergency department
Patient selection: low; index test:
low; reference standard: low; flow
and timing: low; overall: low
Retrospective review by
two cardiologists
NTproBNP Elecsys
(Roche, USA),
MRproANP LIA
(B.R.A.H.M.S,
Germany)
154/287
(54)
149/138Prospective
cohort
287 (77)Potocki 2010,41
emergency department
Patient selection: low; index test:
low; reference standard: low; flow
and timing: low; overall: low
Retrospective review by
two cardiologists
BNP Abbott Architecht
(Abbott Diagnostics,
Netherlands)
49/84 (58)40/44Prospective
cohort
84 (73.5)Wang 2010,42
emergency department
Patient selection: low; index test:
low; reference standard: low; flow
and timing: low; overall: low
Retrospective review by
one cardiologist and one
geriatrician
BNP Triage (Biosite,
USA)
26/64 (41)20/44Prospective
cohort
64 (84.3)Blonde-Cynober 2011,43
inpatients
Patient selection: low; index test:
low; reference standard: low; flow
and timing: low; overall: low
Final hospital diagnosis
confirmed by
cardiologists and or
intensivists
NTproBNP Elecsys
(Roche, USA)
129/218
(59)
NRProspective
cohort
218 (NR)Prosen 2011,44
prehospital emergency
Patient selection: low; index test:
high; reference standard: high;
flow and timing: low; overall: high
Cardiology discharge
diagnosis
NTproBNP Elecsys
(Roche, USA)
79/100 (79)48/52Cross
sectional
100 (61)Shaikh 2011,45
emergency department
Patient selection: low; index test:
low; reference standard: low; flow
and timing: low; overall: low
Retrospective review by
two cardiologists
NTproBNP Elecsys
(Roche, USA)
362/632
(57)
NRProspective
cohort
632 (NR)Eckstein 2012,46
emergency department.
Overlap with Maisel
201040 data. Data only
extracted for NTproBNP
to avoid double counting
for MRproANP
BNP=B type natriuretic peptide; NTproBNP=N terminal probrain natriuretic peptide; MRproANP=mid-regional proatrial natriuretic peptide; NR=not recorded.
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Table 2| Sensitivity, specificity, positive predictive and negative predictive values for all peptides. Values in brackets are pooled 95%
confidence intervals or range*
I2 (%)Negative predictive
value
Positive predictive
valueSpecificity %Sensitivity %
No of
casesNo
No of
studies
Natriuretic peptide
(threshold)
B type natriuretic
peptide:
980.94 (0.90 to 0.96)0.67 (0.63 to 0.75)0.63 (0.52 to 0.73)0.95 (0.93 to 0.96)3049695019≤100 ng/L
970.86 (0.82 to 0.89)0.85 (0.78 to 0.90)0.86 (0.79 to 0.91)0.85 (0.81 to 0.88)2160454320100-500 ng/L
—0.55 (0.69-0.80) to
0.69 (0.48-0.84)*
0.89 (0.75-0.96) to 1.0
(0.63-1.0)*
0.78 (0.56-0.93) to
1.00 (0.91-1.00)*
0.35 (0.17-0.56) to
0.83 (0.69-0.92)*
1452834≥500 ng/L
N terminal probrain
natriuretic peptide:
940.98 (0.89 to 1.0)0.64 (0.57 to 0.73)0.43 (0.26 to 0.62)0.99 (0.97 to 1.00)1695334910≤300 ng/L
970.88 (0.82 to 0.92)0.80 (0.74 to 0.84)0.76 (0.69 to 0.82)0.90 (0.86 to 0.93)1652322313300-1800 ng/L
—0.71 (0.65-0.76) to
0.82 (0.73-0.89)*
0.80 (0.73-0.86) to
0.94 (0.89-0.97)*
0.72 (0.63-0.80) to
0.95 (0.91-0.98)*
0.67 (0.60-0.73) to
0.87 (0.81-0.92)*
4448403≥1800 ng/L
Mid-regional proatrial
natriuretic peptide:
—0.90 (0.80-0.96) to
0.97 (0.96-0.98)*
0.56 (0.53-0.59) to
0.72 (0.65-0.79)*
0.56 (0.47-0.65) to
0.60 (0.57-0.63)*
0.95 (0.90-0.98) to
0.97 (0.95-0.98)*
70518922≤120 pmol/L
—0.82 (0.74-0.88) to
0.98 (0.93-1.00)*
0.41 (0.35-0.47) to
0.86 (0.79-0.91)*
0.40 (0.34-0.46) to
0.84 (0.77-0.90)*
0.84 (0.77-0.89) to
0.98 (0.94-1.00)*
4069163>120 pmol/L
*A sensitivity or specificity range is given where there were insufficient number of studies to conduct diagnostic meta-analysis and generate a pooled sensitivity
and specificity value. Table 1 shows the setting of each study and assay used.
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Table 3| Investigation of heterogeneity
Overall study qualityPrevalenceAssaySettingVariables
B type natriuretic peptide
≤100 ng/L:
0.92 (0.84 to 0.96)0.96 (0.92 to 0.98)0.94 (0.91 to 0.96)0.95 (0.91 to 0.97)Sensitivity (95% CI)
0.130.50.60.89P value
0.69 (0.43 to 0.87)0.62 (0.36 to 0.83)0.66 (0.49 to 0.79)0.56 (0.38 to 0.72)Specificity (95% CI)
0.640.960.760.51P value
100-500 ng/L:
0.80 (0.68 to 0.88)0.82 (0.71 to 0.90)0.83 (0.77 to 0.88)0.87 (0.82 to 0.91)Sensitivity (95% CI)
0.290.620.680.37P value
0.92 (0.78 to 0.97)0.89 (0.73 to 0.96)0.90 (0.81 to 0.95)0.81 (0.69 to 0.89)Specificity (95% CI)
0.360.650.450.38P value
N terminal probrain natriuretic peptide
≤300 ng/L:
0.98 (0.90 to 1.00)0.98 (0.93 to 1.00)0.96 (0.77 to 0.99)0.99 (0.97 to 0.99)Sensitivity (95% CI)
0.560.810.210.97P value
0.56 (0.15 to 0.90)0.93 (0.84 to 0.97)0.42 (0.06 to 0.89)0.77 (0.57 to 0.89)Specificity (95% CI)
058<0.01*0.370.53P value
N terminal probrain natriuretic peptide
300-1800 ng/L:
0.91 (0.81 to 0.96)0.93 (0.84 to 0.97)0.92 (0.72 to 0.98)0.90 (0.85 to 0.94)Sensitivity (95% CI)
0.820.460.750.91P value
0.78 (0.62 to 0.88)0.84 (0.71 to 0.92)0.58 (0.30 to 0.82)0.78 (0.70 to 0.85)Specificity (95% CI)
0.830.220.170.67P value
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Figures
Fig 1 Paired sensitivity and specificity plots for B type natriuretic peptide at three threshold levels
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Fig 2 Results for B type natriuretic peptide (separated by threshold) displayed in summary receiver operating characteristic
space. Size of symbol indicates study size and solid circles show pooled sensitivity or specificity value (for >500 ng/L
insufficient data were available to pool results)
Fig 3 Paired sensitivity and specificity plots for N terminal probrain natriuretic peptide at three threshold levels
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Fig 4 Results for N terminal probrain natriuretic peptide (separated by threshold) displayed in summary receiver operating
characteristic space. Size of symbol indicates study size and solid circles show pooled sensitivity or specificity value
according to threshold (for >500 ng/L insufficient data was available to pool results)
Fig 5 Paired sensitivity and specificity plots for mid-regional proatrial natriuretic peptide at two threshold levels
Fig 6 Results for mid-regional proatrial natriuretic peptide (separated by threshold) displayed in summary receiver operating
characteristic space. Size of symbol indicates study size
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Fig 7Comparison of pooled B type natriuretic peptide and N terminal probrain natriuretic peptide diagnostic accuracy results
at lowest threshold (95% confidence region indicated as circles surrounding solid points)
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